ArticleJournal of viral hepatitis2025
Assessment of Hemophagocytic Lympho-Histiocytosis (HLH) in the Setting of Adult Acute Liver Failure.
Article in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of Hemophagocytic Lympho-Histiocytosis (HLH) in the Setting of Adult Acute Liver Failure.Journal of viral hepatitis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lympho-histiocytosis (HLH) is a life-threatening disease, only occasionally presenting as acute liver failure (ALF) in adults. HLH is challenging to diagnose. We reviewed the ALF Study Group (ALFSG) registry for suspected HLH subjects, as well as 184 with other ALF etiologies for cases that might have been missed, assessing standard laboratory tests, as well as interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2r), to determine the diagnostic utility of these biomarkers. We also calculated standard diagnostic algorithms (H score, HLH-2004 diagnostic criteria) to assess their value. Within 3364 ALF subjects, only 14 were initially cited as HLH. Upon thorough review by an adjudication committee, 5/14 (35.7%) were considered definite, five probable, two possible, and two unlikely. Definite HLH patients had significantly higher ferritin (p = 0.047), IL-18 (p = 0.003) and s-IL2r (p = 0.005) levels, H scores (p < 0.001) and HLH scores (p < 0.001). Other etiologies (APAP, DILI and viral) showed lower IL-18 and sIL2r levels and scores, but overlapping ferritins. Several probable/possible HLH cases lacked complete data for scoring. No additional (missed) HLH cases were identified. HLH remains a rare cause of ALF. Biomarkers, particularly IL-18 and sIL-2r, appear of value. HLH and H scores were also helpful but limited when data was missing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.